MARTINSRIED, Germany, Sept. 24, 2008 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE:MOR) (Prime Standard Segment:TecDAX) announced today that it has exercised its first option to participate in the development of a therapeutic antibody program within its collaboration with Novartis. In a first, pre-development step, Novartis will fund the companies’ joint efforts until the program reaches formal pre-clinical development. MorphoSys will recognize its share of the funding as additional revenues.
